

Applicants: Alan R. Tall et al.

Serial No.: 09/898,554

Filed: July 2, 2001

Page 2

Please amend claims 5 and 41 as follows:

C1
5. (Twice Amended) A nucleic acid probe of at least 15 nucleotides in length which specifically hybridizes with a nucleic acid encoding a mammalian oxidized, low-density lipoprotein receptor (LOX-1) or with a nucleic acid having the complementary sequence thereof.

C2
41. (Amended) An isolated nucleic acid encoding a protein comprising the amino acid sequence set forth in SEQ ID NO:14.

Please add new claims 51-60 as follows:

51. (New) A vector comprising the nucleic acid of claim 41.

52. (New) The nucleic acid of claim 41, wherein the nucleic acid has the sequence set forth in SEQ ID NO:13.

C3
53. (New) The vector of claim 51, wherein the vector is adapted for expression of the nucleic acid in a cell and comprises regulatory elements necessary for expression of the nucleic acid in the cell operatively linked to the nucleic acid so as to permit expression thereof.

54. (New) An isolated cell comprising the vector of claim 51.

55. (New) The nucleic acid of claim 41, wherein the nucleic acid is DNA or RNA.

Applicants: Alan R. Tall et al.

Serial No.: 09/898,554

Filed: July 2, 2001

Page 3

56. (New) The nucleic acid of claim 55, wherein the DNA is cDNA.

57. (New) The cell of claim 54, wherein the cell is a bacterial, amphibian, yeast, fungal, insect, or mammalian cell.

58. (New) The cell of claim 54, wherein but for the vector present therein, the cell would not express a mammalian oxidized, low-density lipoprotein (LOX-1) receptor.

C3
59. (New) A membrane preparation comprising a mammalian oxidized, low-density lipoprotein receptor (LOX-1) isolated from the cell of claim 58.

60. (New) A soluble cell extract comprising a mammalian oxidized, low-density lipoprotein receptor (LOX-1) isolated from the cell of claim 58.

A marked-up version of amended claims 5 and 41 showing the changes made is attached hereto as **Exhibit 1**.

REMARKS

Claims 1, 2, 5, 9-12, and 37-50 are pending in the subject application. Of the above claims, claims 9 and 42-46 were withdrawn from consideration by the Examiner. By this Amendment, applicants cancel claims 1, 2, 10-12, 37, 38, and 47-50 without prejudice or disclaimer, add new claims 51-60, and amend claims 5 and 41.